The fate of genetic data belonging to millions of 23andMe customers is again up in the air, as the bankrupt company seeks a judge’s permission to consider another bid from its co-founder and ...

MoonLake Immunotherapeutics shares surged 31% after the Financial Times reported, citing unnamed sources, that the company had rejected an initial acquisition offer by Merck & Co. for more than $3 ...